1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Fresenius Is Latest To File Denosumab With US FDA

While Henlius Confirms EMA Acceptance Of Its European Prolia/Xgeva Biosimilar Filing

 
• By Dave Wallace

With activity around denosumab biosimilars continuing to heat up, Fresenius Kabi has announced US FDA acceptance of its filing, while China’s Henlius says the EMA is reviewing its own biosimilar submission.

WHITE OAK, MD - JULY 20: A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Photo by Sarah Silbiger/Getty Images)
Fresenius has filed its denosumab biosimilar in the US • Source: Sarah Silbiger/Getty Images (Sarah Silbiger/Getty Images)

Fresenius Kabi has become the latest company to confirm a US Food and Drug Administration filing for a Prolia/Xgeva (denosumab) biosimilar, announcing that its version has now been accepted for review by the US agency.

The firm had reported midway through last year that its FKS518 candidate referencing Prolia (denosumab) successfully met its primary and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.

IGBA Asks G7 To Consider Access Issues

 
• By Dave Wallace

The International Generic and Biosimilar medicines Association has set out three priority areas that it says should be considered by G7 leaders at the current summit in Alberta, Canada, as part of efforts towards ensuring access to health.

Outlook Launches Ophthalmic Bevacizumab In Germany And The UK

 
• By Urtė Fultinavičiūtė

Outlook Therapeutics has started to conquer European markets with its ophthalmic version of bevacizumab. Meanwhile, across the pond in the US, it awaits the FDA’s decision, again.

Reshaped Xbrane Allies With OneSource For Commercial Biosimilar Manufacturing

 
• By Dean Rudge

Xbrane Biopharma is partnering with India’s OneSource Specialty Pharma to manufacture its biosimilars, including its much-delayed ranibizumab product Ximluci. The move follows a SEK240m funding round and strategic refocus on commercialization after divesting key R&D assets to Alvotech.

More from Products

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

‘I Saw An Unpolished Diamond’: Iconovo CEO Wäborg On Breaking Even In 2027 And Beyond

 
• By Dean Rudge

In an exclusive interview, Iconovo CEO Johan Wäborg outlines the company’s strategy to become a leader in dry powder inhalation by focusing on platform development, reformulated therapies, and B2B licensing, with a plan to break even by 2027.

Lupin Looks To Expand In China With Respiratory Alliance

 
• By Dave Wallace

Lupin is planning to expand its footprint in China through a deal for a tiotropium dry powder inhaler with local player Sino Universal Pharmaceuticals.